PURCHASE, N.Y. -- In an effort to help the victims of SARS in Hong Kong maintain a healthy immune response, Quality of Life Labs, Inc., has made arrangements with the Hong Kong Ministry of Health to ship 300 bottles ($30,000 value) of ImmunoKinoko AHCC to assist in their efforts. Additional ImmunoKinoko will be provided over the upcoming months.
ImmunoKinoko AHCC contains Active Hexose Correlated Compound, a Japanese medicinal mushroom extract used to strengthen the immune system. The ingredient is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan.
While no one knows what causes SARS yet, it is clear that the vast majority of diseases we come into contact with on a daily basis can be managed by the body s immune system, stated Fred Pescatore, MD, MPH and medical director of the AHCC Research Association. By providing some of those who are suffering with ImmunoKinoko AHCC, we hope we can help them remain healthy until a cure is discovered for this mysterious flu-like illness. Also, we would like to alert the public how important it is to strengthen the immune system during times of crises.
To date, more than 2,630 cases and 95 deaths have been reported in 17 countries in Asia, Europe and North America since mid-November, when SARS emerged in China.
ImmunoKinoko AHCC is packaged in bottles of 60 capsules, 500 mg each, with a suggested daily use of two to six capsules daily. According to industry analysts in Japan, more than 700 hospitals and medical clinics currently recommend AHCC to patients in that country as part of an immune support regimen.
Quality of Life Labs, sister company to Maypro Industries, Inc. located in Purchase, N.Y., is the sole U.S. distributor of AHCC.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
CDC HICPAC Considers New Airborne Pathogen Guidelines Amid Growing Concerns
November 18th 2024The CDC HICPAC discussed updates to airborne pathogen guidelines, emphasizing the need for masks in health care. Despite risks, the committee resisted universal masking, highlighting other mitigation strategies
Breaking the Cycle: Long COVID's Impact and the Urgent Need for Preventative Measures
November 15th 2024Masking, clean air, and vaccinations are essential in combating COVID-19 and preventing long-term impacts, as evidence mounts of long COVID's significant economic, cognitive, and behavioral effects.
The Critical Role of Rapid Diagnostics in Antibiotic Stewardship
November 6th 2024Rapid diagnostics enhance patient outcomes by enabling prompt, targeted treatments, reducing inappropriate antibiotic use, and combating antimicrobial resistance through informed clinical decisions and stewardship programs.